We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.03B
1-Year Est. Return 214.94%
This Fund
S&P 500
This Quarter Est. Return
-13.51%
1 Year Est. Return
+214.94%
3 Year Est. Return
+1,814.37%
5 Year Est. Return
+1,842.35%
10 Year Est. Return
–
AUM
$561M
AUM Growth
-$168M
Cap. Flow
+$64.3M
Cap. Flow %
11.47%
Top 10 Hldgs %
86.32%
Holding
44
New
1
Increased
3
Reduced
8
Closed
7

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$112M
2
MLYS icon
Mineralys Therapeutics
MLYS
+$6.9M
3
SEPN
Septerna Inc
SEPN
+$4.35M
4
SRZN icon
Surrozen
SRZN
+$2.81M

Top Sells

Rank Stock Value
1
JSPR icon
Jasper Therapeutics
JSPR
+$12.5M
2
LENZ
LENZ Therapeutics
LENZ
+$11.3M
3
ACLX
Arcellx
ACLX
+$8.02M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$5.91M
5
CLYM
Climb Bio
CLYM
+$4.7M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TNGX icon
26
Tango Therapeutics
TNGX
$4.41B
$863K 0.15%
630,000
– –
PRME icon
27
Prime Medicine
PRME
$559M
$806K 0.14%
405,228
– –
CYPH
28
Cypherpunk Technologies Inc
CYPH
$73.3M
$745K 0.13%
2,442,352
– –
HLVX
29
DELISTED
HilleVax
HLVX
$579K 0.1%
399,637
– –
TERN
30
DELISTED
Terns Pharmaceuticals
TERN
$558K 0.1%
202,348
– –
BOLT icon
31
Bolt Biotherapeutics
BOLT
$7.78M
$420K 0.07%
52,458
– –
CRIS icon
32
Curis
CRIS
$7.83M
$390K 0.07%
9,297
-614
-6% -$38K
LYRA
33
DELISTED
LYRA THERAPEUTICS INC
LYRA
$176K 0.03%
27,803
-11,511
-29% -$108K
KRON
34
DELISTED
Kronos Bio
KRON
$64.5K 0.01%
78,131
– –
NUVB.WS
35
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$42.7K 0.01%
133,333
– –
ALLK
36
DELISTED
Allakos
ALLK
$39.2K 0.01%
172,089
– –
SRZNW icon
37
Surrozen Inc Warrant
SRZNW
$8.86K
$3K ﹤0.01%
99,999
– –
ACRS icon
38
Aclaris Therapeutics
ACRS
$869M
– –
-2,385,060
Closed -$5.91M
DAWN
39
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-147,319
Closed -$1.87M
IMTX icon
40
Immatics
IMTX
$1.32B
– –
-198,000
Closed -$1.41M
JANX icon
41
Janux Therapeutics
JANX
$967M
– –
-11,263
Closed -$603K
JSPR icon
42
Jasper Therapeutics
JSPR
$23.6M
– –
-584,642
Closed -$12.5M
VRNA
43
DELISTED
Verona Pharma
VRNA
– –
-97,625
Closed -$4.53M
CLYM
44
Climb Bio
CLYM
$804M
– –
-2,609,114
Closed -$4.7M
1
2

Similar funds

MA
Madrone Advisors Menlo Park, California $1.03B AUM 20.53% 1-Year Est. Return
WHCM
Wolf Hill Capital Management Greenwich, Connecticut $1.03B AUM 80.44% 1-Year Est. Return
JSC
J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return
IAS
IMA Advisory Services Denver, Colorado $1.02B AUM 18.66% 1-Year Est. Return
CM
Condire Management Dallas, Texas $1.03B AUM 162.78% 1-Year Est. Return
CFFNO
Common Fund For Nonprofit Organizations Wilton, Connecticut $1.03B AUM 22.44% 1-Year Est. Return
MSA
Mason Street Advisors Milwaukee, Wisconsin $1.02B AUM 8.35% 1-Year Est. Return
TBA
Tower Bridge Advisors Conshohocken, Pennsylvania $1.04B AUM 23.66% 1-Year Est. Return

Samsara BioCapital's Q1 2025 Portfolio in Review

As of Q1 2025, Samsara BioCapital held 44 positions worth $561M, down 23% from $729M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Samsara BioCapital deployed $64.3M of net new capital in Q1 2025, opening 1 new position and adding to 3 existing holdings. Its largest new stake was Surrozen: 241,400 shares worth $2.81M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was LENZ Therapeutics, an estimated $11.3M trimmed.

  • Samsara BioCapital's largest Q1 2025 buy was Surrozen: 241,400 shares worth $2.81M.
  • Samsara BioCapital added most to Kalaris Therapeutics in Q1 2025, an estimated $112M increase.
  • Samsara BioCapital's biggest Q1 2025 reduction was LENZ Therapeutics, cutting an estimated $11.3M.
  • Samsara BioCapital fully exited Jasper Therapeutics in Q1 2025, selling an estimated $12.5M.
  • Samsara BioCapital's ten largest holdings make up 86% of its $561M portfolio in Q1 2025.
  • Samsara BioCapital opened 1 new position and closed 7 in Q1 2025.
  • Samsara BioCapital's portfolio value fell 23% quarter-over-quarter to $561M.

Based on Samsara BioCapital's 13F filing for Q1 2025, filed 15 May 2025.